Benzinga | Oct 15, 2021 09:17AM EDT

Cantor Fitzgerald Maintains Neutral on Biogen, Lowers Price Target to $327

Cantor Fitzgerald analyst Alethia Young maintains Biogen (NASDAQ:BIIB) with a Neutral and lowers the price target from $427 to $327.